27 results about "Ocular hypertension" patented technology

The invention belongs to the technical field of medicines, and discloses an application of a Necrosulfenamide (NSA) compound in preparation of a medicine for resisting glaucoma trabecular network fibrosis. The NSA can inhibit abnormal activation of necroptosis-related pathways and significantly down-regulate fibrosis key factors, so that the structure and function of trabecular meshwork tissues are improved, and the aqueous humor outflow capacity is recovered. It is found for the first time that NSA not only has a stable and lasting intraocular pressure lowering effect, but also can reduce retinal ganglion cell damage in an intraocular hypertension state, and has definite treatment and protection effects on non-acute glaucoma and intraocular hypertension. The regulation effect of NSA on trabecular meshwork fibrosis is not disclosed in the prior art, the research blank in the field is filled, and a new pharmacological target and a clinical application strategy are provided for prevention and treatment of glaucoma and related intraocular hypertension diseases.

Disclosed are a series of isoquinolone derivatives as ROCK protein kinase inhibitors and uses thereof in preparing medicaments for ROCK protein kinase inhibitor-related glaucoma or ocular hypertension diseases. Specially, disclosed are a compound of formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

The present invention relates to the technical field of pharmaceuticals, and in particular to a class of nitric oxide (NO) donor-containing compounds or pharmaceutically acceptable salts, a preparation method therefor, a pharmaceutical composition, and a use thereof in the treatment or prevention of an ocular hypertension-related ophthalmic disease and an optic nerve injury-related disease.

The present technology provides systems, devices, and methods for forming blebs to treat ocular hypertension or glaucoma. In some embodiments, a minimally invasive bleb formation device comprises an introducer sheath having a lumen extending longitudinally therethrough. The lumen has a distal end aperture insertable adjacent to a target tissue. The device further includes a wire positionable within the lumen of the introducer sheath. The wire has a first end portion, a second end portion, and an intermediate region between the first end portion and the second end portion. At least a segment of the intermediate portion is configured to extend through the distal end aperture to form a wire loop. The wire loop is moveable between a plurality of positions and is configured to disrupt and cauterize the target tissue.

Provided herein are solid forms, e.g., polymorphs, of 2-(3-((7R,8aS)-7-fluorohexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)-1-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)azetidin-3-yl)acetonitrile, which are useful for treating kinase-related diseases or disorders. The solid forms, and compositions thereof, are useful for treating diseases in a subject, including, but not limited to, ocular diseases such as glaucoma, ocular hypertension, ocular wound repair, neurodegenerative ocular diseases, retinal detachment, and non-ocular diseases such as nerve injury, or skin wound repair, or inflammatory diseases, among others. (Compound 1) TIFF2026501674000028.tif4839

This disclosure relates to a drug delivery system comprising an intraocular pressure lowering agent, a neurotrophic agent, such as a CNTF compound, a C-type Natriuretic Peptide (CNP) compound, a Tie-2 agonist, a Natriuretic Peptide Receptor-B (NPR-B) compound, or an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, including any combination of these compounds and a sustained delivery component. Methods of treating a glaucoma or related conditions, medicaments, kits, uses and methods of manufacturing are also described.

The present disclosure relates to a drug delivery system comprising an intraocular pressure-lowering agent, a neurotrophic agent such as a CNTF compound, a C-type natriuretic peptide (CNP) compound, a Tie-2 agonist, a natriuretic peptide receptor B (NPR-B) compound, or an apoptosis signaling fragmentation inhibitor (FAS) or FAS ligand (FASL) inhibitor (including any combination of these compounds), and a sustained-delivery component. Methods, medicaments, kits, methods of use, and methods of manufacture for treating glaucoma or related conditions are also disclosed. [Selection diagram] None

The invention discloses a dual-channel drug delivery treatment system for open-angle glaucoma night intraocular hypertension, and relates to the technical field of medical instruments and clinical assistance. The system comprises a central control module, a time window control module, an intelligent double-medicine-bin medicine feeding module, a user interaction module, a data management and analysis module, a communication module, a safety and self-checking module and a power supply and management module. According to the invention, through the time window control module, the traditional morning administration is changed into night administration or individualized administration before intraocular pressure peak, the synchronization of the drug action peak and the night intraocular pressure peak is ensured, and through the intelligent double-drug-bin administration module and the precise metering pump, two drugs with the lowest effective dose are precisely delivered strictly according to the specific sequence of PGA first and CAI second; the time sequence control and precise quantitative administration based on the drug synergistic effect mechanism can ensure the synergistic antihypertensive curative effect, and can obviously avoid the high incidence rate adverse reaction caused by standard dosage combination.

Provided herein are compounds comprising a formula of 4-(3- amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-y I) benzyl adamantane carboxylate (e.g., compounds of formula (I) ) or a pharmaceutically acceptable salt thereof. The compounds are useful for reducing intraocular pressure and for treating glaucoma or ocular hypertension. Formula (I).

The present application relates to a nitric oxide donor-type compound and use thereof in the preparation of a medicament for preventing and / or treating ophthalmic diseases such as glaucoma and ocular hypertension. The compound has a structure represented by formula (I), or is a stereoisomer, tautomer, solvate, metabolite, pharmaceutically acceptable salt, or prodrug of the structure represented by formula (I).

To provide ophthalmic devices and methods for treating glaucoma, ocular hypertension (OHT), and other diseases. [Solution] The system (20) comprises a radiation source (48) and a controller (44), the controller being configured to: display a live sequence of images of the patient's (22) eye (25); while displaying the sequence of images of the eye, to direct the radiation source to irradiate the eye with one or more targeting beams (84) visible in the images; after directing the targeting beams to the eye with the radiation source, to receive confirmation input from the user; and in response to receiving confirmation input, to treat the eye by directing the radiation source to irradiate each target area of ​​the eye with multiple treatment beams. Other embodiments are also described.

To provide a technique for suppressing crystal precipitation during low-temperature storage of an aqueous composition containing a halogenated isoquinoline derivative.SOLUTION: There is provided a pharmaceutical preparation for the prevention or treatment of one or more diseases selected from ocular hypertension and glaucoma, where an aqueous composition containing a compound represented by the general formula (1) in the figure [where X represents a halogen atom] or a salt thereof, or a solvate of them, is contained in a container made of a polyester-based resin.SELECTED DRAWING: None

The present invention relates to pharmaceutical composition comprising the beta 1 (β1)-receptor blocker timolol and a liquid vehicle comprising a semifluorinated alkane. The pharmaceutical composition of the present invention may be useful for topical administration, for example ophthalmic topical administration and for use in the treatment of glaucoma, increased intraocular pressure, ocular hypertension and / or a symptom associated therewith.

The present invention provides a compound having an mPGES-1 inhibitory activity and useful for the prophylaxis or treatment of pain, rheumatism, osteoarthritis, fever, Alzheimer's disease, multiple sclerosis, arteriosclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma and / or cancer including colorectal cancer.The present invention relates to a compound of formula [I-a], [I-b] or [I-c] or a pharmaceutically acceptable salt thereof:wherein each symbol is as defined in the specification.

Disclosed herein are methods, devices, and systems for monitoring fluid outflow behavior of an eye of a subject, for example, during ocular surgery. Changes to intraocular pressure can reflect fluid outflow behavior. Fluid outflow behavior can be a critical factor in the successful outcome of a surgery and determining likelihood of post-operative side effects. Large fluctuations in intraocular pressure, ocular hypertension, and hypotony can be associated with vision loss or poor ocular health.

Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. Methods for making and using the implants to reduce ocular hypertension and intraocular pressure in a patient are described.

The invention belongs to the technical field of biological medicine, and particularly relates to a soluble microneedle patch for in-situ drug delivery of trabecular meshwork tissue and a preparation method and application of the soluble microneedle patch. The soluble microneedle patch comprises a fan-ring-shaped backing and a microneedle array arranged on the fan-ring-shaped backing; the micro-needle and the fan-ring-shaped backing are both prepared from polyvinyl alcohol (PVA), the PVA concentration for preparing the micro-needle and the fan-ring-shaped backing is 5%-25%, and the PVA concentration is obtained by weighing 0.5 g-2. 5 g of PVA powder and dissolving the PVA powder in 10 mL of pure water or PBS. The microneedle patch is suitable for delivery of various types of drugs, is expected to be used for treatment of various eye diseases including glaucoma, ocular hypertension, cataract, uveitis, conjunctivitis, xerophthalmia and the like, and has important clinical application value and commercial value.

Nitric oxide releasing phosphodiesterase type 5 (PDE5) inhibitors of formula (I) or (Ib) or (II) or a stereoisomer or a pharmaceutically acceptable salt thereof:useful for the treatment of ocular condition associated with elevated intraocular pressure such as ocular hypertension, glaucoma or retinopathies. Also disclosed are 3-[(2S)-2,3-bis(nitrooxy)propoxy]propanoic acid and 6-(nitrooxy)hexanoic acid for use in the treatment of ocular condition associated with elevated intraocular pressure such as ocular hypertension, glaucoma or retinopathies.

Provided herein are compounds comprising a formula of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl adamantane carboxylate (e.g., compounds of formula (I) or formula (II)) or a pharmaceutically acceptable salt thereof. The compounds are useful for reducing intraocular pressure and for treating glaucoma or ocular hypertension.

The invention relates to the technical field of medicine, in particular to a compound containing a nitric oxide (NO) donor or pharmaceutically acceptable salt, a preparation method of the compound or the pharmaceutically acceptable salt, a pharmaceutical composition of the compound or the pharmaceutically acceptable salt, and application of the compound or the pharmaceutically acceptable salt to treatment or prevention of ophthalmic intraocular hypertension related diseases and optic nerve injury related diseases.

This invention belongs to the field of biotechnology and discloses the application of S100A9 inhibitors in the preparation of drugs for treating acute ocular hypertension-induced retinal injury. The study showed that the inflammation scores of AH patients in I / R model mice with APACG were significantly elevated, indicating a marked activation of inflammatory pathways. By comparing differentially expressed mediators, the pro-inflammatory alarmist S100A9 was screened. In vivo experiments confirmed that injection of the S100A9-targeting inhibitor Paquinimod significantly reduced ocular hypertension-induced retinal inflammation, decreased RGC death, and protected retinal structure and function. In vitro experiments confirmed that inhibiting S100A9 expression reduced the levels of inflammatory cytokines in microglia undergoing OGD / R. Furthermore, scRNA-seq analysis confirmed that inhibiting S100A9 upregulated Trem2 expression, thereby providing protection against high IOP-induced retinal injury, suggesting that the S100A9 / TREM2 signaling axis plays a crucial endogenous regulatory role in acute glaucoma-induced retinal neuroinflammation. Inhibition of this signaling axis can produce a neuroprotective effect by inhibiting the excessive activation of retinal microglia.

Disclosed is a salt form of an isoquinolinone type compound as a ROCK protein kinase inhibitor and a preparation method therefor, and use of the salt form in the preparation of a medicament for treating glaucoma or ocular hypertension is further included.

To provide ophthalmic devices and methods for treating glaucoma, ocular hypertension (OHT), and other diseases. [Solution] The system comprises a radiation source (48) and a controller (44). The controller is configured to: designate multiple target regions (84) of the patient's (22) eye (25) to irradiate with different amounts of energy; cause the radiation source to irradiate at least a first target region of the multiple target regions; after causing the radiation source to irradiate at least a first target region of the multiple target regions, process an image of the eye to identify changes in the eye; and in response to the identification of changes in the eye, cause the radiation source to refrain from irradiating a second target region of the multiple target regions that have not yet been irradiated with the amount of energy specified for the second target region. Other embodiments are also described.

The invention relates to the technical field of medicine, in particular to a compound containing a nitric oxide (NO) donor or pharmaceutically acceptable salt, a preparation method of the compound or the pharmaceutically acceptable salt, a pharmaceutical composition of the compound or the pharmaceutically acceptable salt, and application of the compound or the pharmaceutically acceptable salt to treatment or prevention of ophthalmic intraocular hypertension related diseases and optic nerve injury related diseases.

The present disclosure provides ophthalmic dual and triple compound medicine compositions for treating glaucoma and ocular hypertension. Through a salt modification technology, stability of the medicine compositions is improved remarkably. The dual compound medicine composition is prepared from netarsudil free alkali or pharmaceutically acceptable salts of the same and a β-adrenergic receptor blocker. The triple compound medicine composition is prepared from the netarsudil free alkali or the pharmaceutically acceptable salts of the same, the β-adrenergic receptor blocker and a prostaglandin analog. The dual and triple compound medicine compositions have excellent stability when pH is in a range from 4.5 to 5.4, an effective dose of the medicine composition of the present disclosure is applied to eyes of a patient in need once a day at bedtime or close to bedtime, an intra-ocular pressure can be reduced efficiently and quickly, the intra-ocular pressure remains in a physiological range for a longer time, side effects are minor, and patient compliance is high.